8-K: Cingulate Inc. Amends Executive Employment Agreement, Adjusting Compensation Structure

Cingulate Inc. has amended the employment agreement of its Executive Vice President and Chief Medical Officer, Matthew N. Brams, changing his compensation structure to an annual base salary and annual equity grants.

Summary

• Cingulate Inc. has amended the employment agreement for Matthew N. Brams, the Executive Vice President and Chief Medical Officer.
• The amendment, effective January 1, 2025, changes Mr. Brams' compensation structure.
• His new annual base salary is set at $165,000, reflecting a part-time, 50% of full-time equivalent, role.
• Mr. Brams will no longer receive quarterly equity grants but will continue to be eligible for annual equity grants as determined by the Compensation Committee.
• The amendment does not alter other provisions of the original employment agreement.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing a routine change in executive compensation. There are no indications of significant positive or negative implications.

Positives

• The amendment provides clarity on the compensation structure for the Chief Medical Officer.
• The annual review of the base salary by the board allows for potential increases in the future.

Negatives

• The removal of quarterly equity grants could be seen as a reduction in overall compensation.

Risks

• Changes in compensation structure could potentially impact employee morale or retention.
• The board's discretion in determining annual equity grants introduces some uncertainty for the executive.

Future Outlook

The executive's base salary will be reviewed annually by the Board, and may be increased, but not decreased except as part of an across-the-board reduction.

Management Comments

• The Company desires to continue to employ the Executive and the Executive desires to be employed by the Company on the terms contained herein.
• The Executive understands that, except when prohibited by applicable law, the Company's benefit plans may be amended by the Company from time to time in its sole discretion.

Industry Context

Changes in executive compensation are common in the pharmaceutical and biotech industries, often reflecting company performance and strategic priorities. This amendment appears to be a standard adjustment to align compensation with the executive's role and responsibilities.

Comparison to Industry Standards

• Executive compensation in the biotech industry varies widely based on company size, stage of development, and individual roles.
• Base salaries for Chief Medical Officers in similar-sized companies can range from $200,000 to over $500,000, with equity grants being a significant component of total compensation.
• The move from quarterly to annual equity grants is not uncommon, as it can align executive incentives with longer-term company performance.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated, which are larger and more established, typically offer higher base salaries and more substantial equity packages to their executives.

Stakeholder Impact

• Shareholders may be interested in the changes to executive compensation as it can impact the company's financial outlook.
• Employees may be interested in the changes to executive compensation as it can impact the company's overall compensation strategy.

Next Steps

• The Compensation Committee will determine the annual equity grant for Mr. Brams.
• The Board will review Mr. Brams' base salary annually.

Key Dates

Keywords

employment agreement, compensation, executive, salary, equity grants, Cingulate Inc., Matthew N. Brams, Chief Medical Officer